Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant fanconi anemia genes

American Journal of Pathology

Volumn 184, Issue 1, 2014, Pages 260-270

  Ghosh, Soma ^a   Sur, Surojit ^a   Yerram, Sashidhar R ^a   Rago, Carlo ^a   Bhunia, Anil K ^a   Hossain, M Zulfiquer ^a   Paun, Bogdan C ^a   Ren, Yunzhao R ^a   Iacobuzio Donahue, Christine A ^b   Azad, Nilofer A ^a   Kern, Scott E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; BRCA2 PROTEIN; FANCONI ANEMIA PROTEIN;

ARTICLE; CANCER CELL; CANCER EPIDEMIOLOGY; CHROMOSOME BREAKAGE; CLINICAL DECISION MAKING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS LINKING; DRUG RESPONSE; DRUG SENSITIVITY; FANCONI ANEMIA; GAMMA RADIATION; GENE MUTATION; GENETIC ENGINEERING; HETEROZYGOTE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HYPERSENSITIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; NULL CELL; PHENOTYPE; PRIORITY JOURNAL; TUMOR REGRESSION;

ACETALDEHYDE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; HUMANS; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890322148     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.09.023     Document Type: Article

References (55)

1. T. Hucl, E. Gallmeier, and S.E. Kern Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials Cell Cycle 6 2007 1336 1341
2. M.W. Deininger, J.M. Goldman, N. Lydon, and J.V. Melo The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells Blood 90 1997 3691 3698
3. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
4. H. Kim, and A.D. D'Andrea Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway Genes Dev 26 2012 1393 1408
5. B. Schuster, K. Knies, C. Stoepker, E. Velleuer, R. Friedl, B. Gottwald-Muhlhauser, J.P. de Winter, and D. Schindler Whole exome sequencing reveals uncommon mutations in the recently identified Fanconi anemia gene SLX4/FANCP Hum Mutat 34 2013 93 96
6. M. Bogliolo, B. Schuster, C. Stoepker, B. Derkunt, Y. Su, A. Raams, J.P. Trujillo, J. Minguillón, M.J. Ramírez, R. Pujol, J.A. Casado, R. Banos, P. Rio, K. Knies, S. Zúniga, J. Benítez, J.A. Bueren, N.G. Jaspers, O.D. Schärer, J.P. de Winter, D. Schindler, and J. Surrallés Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia Am J Hum Genet 92 2013 800 806
7. M.S. van der Heijden, J.R. Brody, E. Gallmeier, S.C. Cunningham, D.A. Dezentje, D. Shen, R.H. Hruban, and S.E. Kern Functional defects in the fanconi anemia pathway in pancreatic cancer cells Am J Pathol 165 2004 651 657
8. E. Gallmeier, E.S. Calhoun, C. Rago, J.R. Brody, S.C. Cunningham, T. Hucl, M. Gorospe, M. Kohli, C. Lengauer, and S.E. Kern Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options Gastroenterology 130 2006 2145 2154
9. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, M. Santarosa, K.J. Dillon, I. Hickson, C. Knights, N.M. Martin, S.P. Jackson, G.C. Smith, and A. Ashworth Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
10. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N.J. Curtin, and T. Helleday Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
11. R. Wooster, and B.L. Weber Breast and ovarian cancer N Engl J Med 348 2003 2339 2347
12. N. McCabe, N.C. Turner, C.J. Lord, K. Kluzek, A. Bialkowska, S. Swift, S. Giavara, M.J. O'Connor, A.N. Tutt, M.Z. Zdzienicka, G.C. Smith, and A. Ashworth Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 2006 8109 8115
13. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M.J. O'Connor, A. Ashworth, J. Carmichael, S.B. Kaye, J.H. Schellens, and J.S. de Bono Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
14. S. Rottenberg, J.E. Jaspers, A. Kersbergen, E. van der Burg, A.O. Nygren, S.A. Zander, P.W. Derksen, M. de Bruin, J. Zevenhoven, A. Lau, R. Boulter, A. Cranston, M.J. O'Connor, N.M. Martin, P. Borst, and J. Jonkers High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc Natl Acad Sci U S A 105 2008 17079 17084
15. S.L. Edwards, R. Brough, C.J. Lord, R. Natrajan, R. Vatcheva, D.A. Levine, J. Boyd, J.S. Reis-Filho, and A. Ashworth Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 2008 1111 1115
16. L.J. Barber, S. Sandhu, L. Chen, J. Campbell, I. Kozarewa, K. Fenwick, I. Assiotis, D.N. Rodrigues, J.S. Filho, V. Moreno, J. Mateo, L.R. Molife, J. De Bono, S. Kaye, C.J. Lord, and A. Ashworth Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor J Pathol 229 2013 422 429
17. H. Heck, and M. Casanova The implausibility of leukemia induction by formaldehyde: a critical review of the biological evidence on distant-site toxicity Regul Toxicol Pharmacol 40 2004 92 106
18. J.R. Ridpath, A. Nakamura, K. Tano, A.M. Luke, E. Sonoda, H. Arakawa, J.M. Buerstedde, D.A. Gillespie, J.E. Sale, M. Yamazoe, D.K. Bishop, M. Takata, S. Takeda, M. Watanabe, J.A. Swenberg, and J. Nakamura Cells deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of formaldehyde Cancer Res 67 2007 11117 11122
19. I.V. Rosado, F. Langevin, G.P. Crossan, M. Takata, and K.J. Patel Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway Nat Struct Mol Biol 18 2011 1432 1434
20. F. Langevin, G.P. Crossan, I.V. Rosado, M.J. Arends, and K.J. Patel Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice Nature 475 2011 53 58
21. J.I. Garaycoechea, G.P. Crossan, F. Langevin, M. Daly, M.J. Arends, and K.J. Patel Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function Nature 489 2012 571 575
22. S.M. Gapstur, E.J. Jacobs, A. Deka, M.L. McCullough, A.V. Patel, and M.J. Thun Association of alcohol intake with pancreatic cancer mortality in never smokers Arch Intern Med 171 2011 444 451
23. M.P. Longnecker, J.A. Berlin, M.J. Orza, and T.C. Chalmers A meta-analysis of alcohol consumption in relation to risk of breast cancer JAMA 260 1988 652 656
24. A. Yokoyama, T. Muramatsu, T. Ohmori, T. Yokoyama, K. Okuyama, H. Takahashi, Y. Hasegawa, S. Higuchi, K. Maruyama, K. Shirakura, and H. Ishii Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics Carcinogenesis 19 1998 1383 1387
25. T.A. Sohn, R. Bansal, G.H. Su, K.M. Murphy, and S.E. Kern High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter Carcinogenesis 23 2002 949 957
26. C. Rago, B. Vogelstein, and F. Bunz Genetic knockouts and knockins in human somatic cells Nat Protoc 2 2007 2734 2746
27. J.M. Sedivy, and A. Dutriaux Gene targeting and somatic cell genetics-a rebirth or a coming of age? Trends Genet 15 1999 88 90
28. J.R. Brody, and S.E. Kern History and principles of conductive media for standard DNA electrophoresis Anal Biochem 333 2004 1 13
29. T. Hucl, C. Rago, E. Gallmeier, J.R. Brody, M. Gorospe, and S.E. Kern A syngeneic variance library for functional annotation of human variation: application to BRCA2 Cancer Res 68 2008 5023 5030
30. E. Gallmeier, T. Hucl, E.S. Calhoun, S.C. Cunningham, F. Bunz, J.R. Brody, and S.E. Kern Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer Cancer Biol Ther 6 2007 654 660
31. M. Goggins, M. Schutte, J. Lu, C.A. Moskaluk, C.L. Weinstein, G.M. Petersen, C.J. Yeo, C.E. Jackson, H.T. Lynch, R.H. Hruban, and S.E. Kern Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas Cancer Res 56 1996 5360 5364
32. E. Gallmeier, and S.E. Kern Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition Cancer Biol Ther 4 2005 703 706
33. M.S. van der Heijden, J.R. Brody, D.A. Dezentje, E. Gallmeier, S.C. Cunningham, M.J. Swartz, A.M. DeMarzo, G.J. Offerhaus, W.H. Isacoff, R.H. Hruban, and S.E. Kern In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor Clin Cancer Res 11 2005 7508 7515
34. J. Murai, S.Y. Huang, B.B. Das, A. Renaud, Y. Zhang, J.H. Doroshow, J. Ji, S. Takeda, and Y. Pommier Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res 72 2012 5588 5599
35. D.W. Lachenmeier, F. Kanteres, and J. Rehm Carcinogenicity of acetaldehyde in alcoholic beverages: risk assessment outside ethanol metabolism Addiction 104 2009 533 550
36. G. Obe, A.T. Natarajan, M. Meyers, and A.D. Hertog Induction of chromosomal aberrations in peripheral lymphocytes of human blood in vitro, and of SCEs in bone-marrow cells of mice in vivo by ethanol and its metabolite acetaldehyde Mutat Res 68 1979 291 294
37. C.E. Vaca, J.L. Fang, and E.K. Schweda Studies of the reaction of acetaldehyde with deoxynucleosides Chem Biol Interact 98 1995 51 67
38. M. Sako, S. Inagaki, Y. Esaka, and Y. Deyashiki Histones accelerate the cyclic 1,N2-propanoguanine adduct-formation of DNA by the primary metabolite of alcohol and carcinogenic crotonaldehyde Bioorg Med Chem Lett 13 2003 3497 3498
39. J.A. Theruvathu, P. Jaruga, R.G. Nath, M. Dizdaroglu, and P.J. Brooks Polyamines stimulate the formation of mutagenic 1,N2-propanodeoxyguanosine adducts from acetaldehyde Nucleic Acids Res 33 2005 3513 3520
40. N. Homann, H. Jousimies-Somer, K. Jokelainen, R. Heine, and M. Salaspuro High acetaldehyde levels in saliva after ethanol consumption: methodological aspects and pathogenetic implications Carcinogenesis 18 1997 1739 1743
41. S. Perez-Miller, H. Younus, R. Vanam, C.H. Chen, D. Mochly-Rosen, and T.D. Hurley Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant Nat Struct Mol Biol 17 2010 159 164
42. C. Juliano, M. Cossu, M.T. Rota, D. Satta, P. Poggi, and P. Giunchedi Buccal tablets containing cysteine and chlorhexidine for the reduction of acetaldehyde levels in the oral cavity Drug Dev Ind Pharm 37 2011 1192 1199
43. P.J. Brooks, M.A. Enoch, D. Goldman, T.K. Li, and A. Yokoyama The alcohol flushing response: an unrecognized risk factor for esophageal cancer from alcohol consumption PLoS Med 6 2009 e50
44. K. Hashimoto, G. Pinkas, L. Evans, H. Liu, Y. Al-Hasan, and L.P. Thompson Protective effect of N-acetylcysteine on liver damage during chronic intrauterine hypoxia in fetal guinea pig Reprod Sci 19 2012 1001 1009
45. E. Asmussen, and O. Boje The effect of alcohol and some drugs on the capacity for work Acta Physiol Scand 15 1948 109 113
46. C. Beyeler, H.U. Fisch, and R. Preisig The disulfiram-alcohol reaction: factors determining and potential tests predicting severity Alcohol Clin Exp Res 9 1985 118 124
47. B. Xia, Q. Sheng, K. Nakanishi, A. Ohashi, J. Wu, N. Christ, X. Liu, M. Jasin, F.J. Couch, and D.M. Livingston Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2 Mol Cell 22 2006 719 729
48. B. Xia, J.C. Dorsman, N. Ameziane, Y. de Vries, M.A. Rooimans, Q. Sheng, G. Pals, A. Errami, E. Gluckman, J. Llera, W. Wang, D.M. Livingston, H. Joenje, and J.P. de Winter Fanconi anemia is associated with a defect in the BRCA2 partner PALB2 Nat Genet 39 2007 159 161
49. F. Zhang, Q. Fan, K. Ren, and P.R. Andreassen PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2 Mol Cancer Res 7 2009 1110 1118
50. R. Buisson, A.M. Dion-Cote, Y. Coulombe, H. Launay, H. Cai, A.Z. Stasiak, A. Stasiak, B. Xia, and J.Y. Masson Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination Nat Struct Mol Biol 17 2010 1247 1254
51. J.Y. Bleuyard, R. Buisson, J.Y. Masson, and F. Esashi ChAM, a novel motif that mediates PALB2 intrinsic chromatin binding and facilitates DNA repair EMBO Rep 13 2012 135 141
52. T. Hayakawa, F. Zhang, N. Hayakawa, Y. Ohtani, K. Shinmyozu, J. Nakayama, and P.R. Andreassen MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks J Cell Sci 123 2010 1124 1130
53. S. Reid, D. Schindler, H. Hanenberg, K. Barker, S. Hanks, R. Kalb, K. Neveling, P. Kelly, S. Seal, M. Freund, M. Wurm, S.D. Batish, F.P. Lach, S. Yetgin, H. Neitzel, H. Ariffin, M. Tischkowitz, C.G. Mathew, A.D. Auerbach, and N. Rahman Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer Nat Genet 39 2007 162 164
54. H. Xiao, K.J. Zhang, and B. Xia Defects of FA/BRCA pathway in lymphoma cell lines Int J Hematol 88 2008 543 550
55. M.C. Villarroel, N.V. Rajeshkumar, I. Garrido-Laguna, A. De Jesus-Acosta, S. Jones, A. Maitra, R.H. Hruban, J.R. Eshleman, A. Klein, D. Laheru, R. Donehower, and M. Hidalgo Personalizing cancer treatment in the age of global genomic analyses: pALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer Mol Cancer Ther 10 2011 3 8